J.P. Morgan·2026-10-19CompanyOverweightAbbVie (ABBV.US) Solid Skyrizi α4β7 Combo Efficacy Should Raise The Bar in Crohn’s Disease
Goldman Sachs·2026-10-19CompanyNeutral$258AbbVie Inc. (ABBV.US): Ph2 IBD Data Update Confirms Impressive Efficacy of Next-Gen Program
HSBC·2026-09-16SectorBuy$300 → $315▲To infinity and beyond......or not? Evaluating the catalyst path to 2027AbbVie·Top pickJohnson & Johnson·Top pickMerck & Co·Top pickBayer·Top pickSanofi·Top pickEli Lilly·Avoid
Bernstein·2026-05-31SectorUS Biopharmaceuticals: US Biopharma: NSCLC read-across from the Ivo & plenary data at ASCO-MRK, BMY, PFE, ABBV
Bernstein·2026-10-25SectorMarket-PerformUS Biopharmaceuticals: US Biopharma @ ESMO-the most impactful data presented thus far (& implications for our coverage)
Bernstein·2026-08-20SectorMarket-Perform$230US Biopharma: As MRNA leads pharma & biotech (much) higher- what's real & what's hype?